Boundless Bio Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
BOLD$2.45-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(15,430) | $(11,719) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 1,328 | 615 |
| Depreciation | 263 | 237 |
| Accretion of investments, net | (972) | (117) |
| Non-cash lease expense | 618 | 533 |
| Other | — | 25 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (701) | (225) |
| Accounts payable and accrued liabilities | (210) | (904) |
| Operating lease liabilities | (672) | (535) |
| Net cash used in operating activities | (15,776) | (12,090) |
| Cash flows from investing activities | ||
| Purchases of investments | (21,025) | (9,994) |
| Maturities of investments | 39,245 | 32,246 |
| Purchases of property and equipment | (83) | (86) |
| Net cash provided by investing activities | 18,137 | 22,166 |
| Cash flows from financing activities | ||
| Proceeds from the exercise of stock options | 59 | 31 |
| Payment of deferred offering costs | (983) | — |
| Net cash provided by / (used in) financing activities | (924) | 31 |
| Net increase in cash and cash equivalents | 1,437 | 10,107 |
| Cash, cash equivalents, and restricted cash at beginning of period | 24,266 | 11,484 |
| Cash, cash equivalents, and restricted cash at end of period | $25,703 | $21,591 |
| Components of cash, cash equivalents, and restricted cash | ||
| Cash and cash equivalents | $25,143 | $21,058 |
| Restricted cash | 560 | 533 |
| Cash, cash equivalents, and restricted cash at end of year | $25,703 | $21,591 |
| Non-cash investing and financing activities | ||
| Deferred offering costs in accounts payable and accrued liabilities | $2,144 | $— |
| Addition to ROU assets | $— | $282 |
| Increase to ROU assets due to remeasurement of lease obligation | $— | $646 |
| Vesting of early exercised stock options | $2 | $52 |
| Unpaid property and equipment purchases | $24 | $26 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.